Zydus Lifesciences, based in Ahmedabad, is gearing up to introduce the vaccine VaxiFlu-4 to combat a new strain of the influenza virus, in accordance with the WHO-recommended composition of quadrivalent influenza virus vaccines for use in the Southern Hemisphere in 2025.
The pharmaceutical company has developed the quadrivalent inactivated influenza vaccine, VaxiFlu-4, at the Vaccine Technology Centre (VTC) in Ahmedabad and will be selling it through Zydus Vaxxicare, a division of the group that focuses on preventives.
The company stated in a stock exchange filing that a quadrivalent vaccine, by covering strains of both influenza A and influenza B, provides broader protection and significantly reduces the risk of vaccine mismatch. The vaccine has received clearance from the Central Drug Laboratory (CDL).
Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, emphasized the importance of preventives in public health, noting that vaccines have the potential to enhance the quality of life. He highlighted the need in India for access to affordable, high-quality vaccines that can address healthcare challenges, with vaccines like VaxiFlu-4 playing a crucial role in annual immunization and preventing flu outbreaks.
On Tuesday, shares of Zydus Lifesciences closed 1.07% lower on the NSE at ₹881.70.
Published on February 26, 2025.
